Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy

GLIA

Volumn 61, Issue 9, 2013, Pages 1456-1470

  Burda, Joshua E ^a   Radulovic, Maja ^a   Yoon, Hyesook ^a   Scarisbrick, Isobel A ^a,b  

^a Mayo School of Graduate Medical Education   (United States)

^b NONE   (United States)

Author keywords

Demyelination; Myelin; Oligodendrocyte; Protease activated receptor; Spinal cord; Thrombin

Indexed keywords

KALLIKREIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELIN BASIC PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEOLIPID PROTEIN; THROMBIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EXCITOTOXICITY; GENE EXPRESSION; IMMUNOREACTIVITY; IN VITRO STUDY; MICROINJECTION; MOUSE; NERVE CELL; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; OLIGODENDROGLIOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD DISEASE;

EID: 84880818884     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22534     Document Type: Article

References (52)

1. Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD. 2011. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 130:248-282.
2. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, Juliano L, Juliano MA. 2006. Substrate specificity of human kallikrein 6: Salt and glycosaminoglycan activation effects. J Biol Chem 281:3116-3126.
3. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ. 1998. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J Neurosci 18:6241-6253.
4. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M. 2002. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 277:24562-24570.
5. Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA. 2004. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J 18:920-922.
6. Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, Jin Y, Schwartz MA, Rodriguez M, Blaber M. 2002. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41:1165-1173.
7. Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C. 2003. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol 170:2638-2646.
8. Chang A, Tourtellotte WW, Rudick R, Trapp BD. 2002. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346:165-173.
9. Christophi GP, Isackson PJ, Blaber S, Blaber M, Rodriguez M, Scarisbrick IA. 2004. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem 91:1439-1449.
10. Drucker KL, Paulsen AR, Giannini C, Decker PA, Blaber SI, Blaber M, Uhm JH, O'Neill BP, Jenkins RB, Scarisbrick IA. 2013. Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro Oncol 15:305-318.
11. Fancy SP, Chan JR, Baranzini SE, Franklin RJ, Rowitch DH. 2011. Myelin regeneration: A recapitulation of development? Annu Rev Neurosci 34:21-43.
12. Fern R, Moller T. 2000. Rapid ischemic cell death in immature oligodendrocytes: A fatal glutamate release feedback loop. J Neurosci 20:34-42.
13. Franklin R. 2002. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 3:705-714.
14. Gingrich MB, Traynelis SF. 2000. Serine proteases and brain damage-Is there a link? Trends Neurosci 23:399-407.
15. Hamill CE, Mannaioni G, Lyuboslavsky P, Sastre AA, Traynelis SF. 2009. Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp Neurol 217:136-146.
16. Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, Kagechika H, Bauer J, Zhao C, Evercooren AB, Chambon P, Ffrench-Constant C, Franklin RJ. 2011. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci 14:45-53.
17. Juliet PA, Frost EE, Balasubramaniam J, Del Bigio MR. 2009. Toxic effect of blood components on perinatal rat subventricular zone cells and oligodendrocyte precursor cell proliferation, differentiation and migration in culture. J Neurochem 109:1285-1299.
18. Jung M, Kramer E, Grzenkowski M, Tang K, Blakemore W, Aguzzi A, Khazaie K, Chlichlia K, von Blankenfeld G, Kettenmann H. 1995. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci 7:1245-1265.
19. Junge CE, Lee CJ, Hubbard KB, Zhang Z, Olson JJ, Hepler JR, Brat DJ, Traynelis SF. 2004. Protease-activated receptor-1 in human brain: Localization and functional expression in astrocytes. Exp Neurol 188:94-103.
20. Keirstead HS, Blakemore WF. 1997. Identification of post-mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. J Neuropathol Exp Neurol 56:1191-1201.
21. Kremer D, Aktas O, Hartung HP, Kury P. 2011. The complex world of oligodendroglial differentiation inhibitors. Ann Neurol 69:602-618.
22. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W. 2008. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749-1758.
23. Lavi E, Constantinescu CS. 2005. Experimental models of multiple sclerosis. New York, NY: Springer. xiii, 901 pp.
24. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. 2006. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 387:637-641.
25. Luo W, Wang Y, Reiser G. 2007. Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 56:331-345.
26. Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E, Arranz AM, Ravid R, Rodriguez-Antiguedad A, Sanchez-Gomez M, Domercq M. 2007. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 27:9525-9533.
27. McCarthy KD, de Vellis J. 1980. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902.
28. Nicole O, Goldshmidt A, Hamill CE, Sorensen SD, Sastre A, Lyuboslavsky P, Hepler JR, McKeon RJ, Traynelis SF. 2005. Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J Neurosci 25:4319-4329.
29. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD. 2006. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem 281:32095-32112.
30. Oldstone MB, Sinha YN, Blount P, Tishon A, Rodriguez M, von Wedel R, Lampert PW. 1982. Virus-induced alterations in homeostasis: Alteration in differentiated functions of infected cells in vivo. Science 218:1125-1127.
31. Scarisbrick IA, Asakura K, Blaber SI, Blaber M, Isackson PJ, Bieto T, Rodriguez M, Windebank AJ. 2000. Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter. Glia 30:219-230.
32. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M. 2002. Activity of a newly identified serine protease in CNS demyelination. Brain 125:1283-1296.
33. Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP. 2006a. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol 178:167-176.
34. Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, Renner DN, Blaber SI, Blaber M, Vandell AG, Bryson AL. 2011. Functional role of kallikrein 6 in regulating immune cell survival. PLoS One 6:e18376.
35. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. 2001. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol 431:347-361.
36. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, Diamandis EP. 2008. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 389:739-745.
37. Scarisbrick IA, Radulovic M, Burda JE, Larson N, Blaber SI, Giannini C, Blaber M, Vandell AG. 2012a. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis. Biol Chem 393:355-367.
38. Scarisbrick IA, Sabharwal P, Cruz H, Larsen N, Vandell AG, Blaber SI, Ameenuddin S, Papke LM, Fehlings MG, Reeves RK, Blaber M, Windebank AJ, Rodriguez M. 2006b. Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur J Neurosci 24:1457-1469.
39. Scarisbrick IA, Towner MD, Isackson PJ. 1997. Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 17:8156-8168.
40. Scarisbrick IA, Yoon H, Panos M, Larson N, Blaber SI, Blaber M, Rodriguez M. 2012b. Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol 22:709-722.
41. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. 2000. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci USA 97:2264-2269.
42. Suo Z, Wu M, Ameenuddin S, Anderson HE, Zoloty JE, Citron BA, Andrade-Gordon P, Festoff BW. 2002. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem 80:655-666.
43. Tripathi R, McTigue DM. 2007. Prominent oligodendrocyte genesis along the border of spinal contusion lesions. Glia 55:698-711.
44. Vandell AG, Larson N, Laxmikanthan G, Panos M, Blaber SI, Blaber M, Scarisbrick IA. 2008. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J Neurochem 107:855-870.
45. Wang H, Ubl JJ, Reiser G. 2002. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 37:53-63.
46. Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, Li P, Xu Q, Liu QS, Goldman SA, Nedergaard M. 2004a. P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med 10:821-827.
47. Wang Y, Richter-Landsberg C, Reiser G. 2004b. Expression of protease-activated receptors (PARs) in OLN-93 oligodendroglial cells and mechanism of PAR-1-induced calcium signaling. Neuroscience 126:69-82.
48. Wilson R, Brophy PJ. 1989. Role for the oligodendrocyte cytoskeleton in myelination. J Neurosci Res 22:439-448.
49. Wolswijk G. 1998. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 18:601-609.
50. Wrathall JR, Li W, Hudson LD. 1998. Myelin gene expression after experimental contusive spinal cord injury. J Neurosci 18:8780-8793.
51. Yousef GM, Diamandis EP. 2001. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 22:184-204.
52. Zarghooni M, Soosaipillai A, Grass L, Scorilas A, Mirazimi N, Diamandis EP. 2002. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin Biochem 35:225-231.